Skip to content
Catalyst

PapersPMID:21566261

Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans.

Aging2011The record ↗

findings
2
compound
1
endpoints
2
no difference found
1
  1. Finding, moderate evidencelowersTriglycerides
  2. Finding, moderate evidenceno difference foundPostprandial blood glucose area under the curve
Study, every finding
RCT · 12 months
Dose studied, every finding
50 mg DHEA once daily for 12 months
  • “DHEA replacement resulted in a significant decrease in plasma triglycerides (DHEA: 120±10 mg/dl to 105±8 mg/dl; Placebo: 103±8 mg/dl to 110±8 mg/dl; p<0.05 within DHEA group; p<0.05 between groups).”
    Population
    men and women aged 65-75 without known diabetes; multivitamin and calcium/vitamin D supplements given to both arms

What did not

  • “Changes in the areas under the curve for glucose and insulin did not differ significantly between the placebo group (panels A and B) and the DHEA group (panels C and D) (glucose, p=0.09; insulin, p=0.52).”
    Population
    men and women aged 65-75 without known diabetes (16 found diabetic on the baseline OGTT and kept in); multivitamin and calcium/vitamin D supplements given to both arms

Study record

Design
randomised controlled trial
Species
human
Population
men and women aged 65-75 y from the Saint Louis area; 1-year randomized double-blind trial followed by a 12-mo open-label extension
Participants
136
Comparator
placebo
Duration
365 days
Endpoints measured
84